BioSight
Companies
Allogene Therapeutics, Inc. logo

ALLO

NASDAQSOUTH SAN FRANCISCO, CA
Allogene Therapeutics, Inc.

Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic CAR T cell therapies for cancer and autoimmune diseases. The company's three core programs include cemacabtagene ansegedleucel for large B-cell lymphoma, ALLO-329 for autoimmune disease, and ALLO-316 for renal cell carcinoma, with multiple clinical readouts anticipated in the second quarter of 2026. Allogene uses TALEN gene-editing technology from Cellectis and CRISPR-based technology from Arbor Biotechnologies to engineer off-the-shelf T cell products designed to minimize graft-versus-host disease while enabling robust anti-tumor or anti-autoimmune activity.

Price history not yet available for ALLO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar